Alliance Global Partners Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $2.2
Alliance Global Partners Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $2.2
Alliance Global Partners维持买入NeuroOne Medical Tech，将目标
Alliance Global Partners analyst Ben Haynor maintains NeuroOne Medical Tech (NASDAQ:NMTC) with a Buy and lowers the price target from $3.25 to $2.2.
Alliance Global Partners分析师本·海诺维持NeuroOne Medical Tech（纳斯达克股票代码：NMTC）的买入，并将目标股价从3.25美元下调至2.2美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。